RBM-007 in Subjects witH ExudatIve Age-related Macular Degeneration (SUSHI)

Phase 1/2 Open Label, Dose-escalation Study of the Safety and OcUlar Tolerability of a Single Intravitreal Injection of RBM-007 in Subjects witH ExudatIve Age-related Macular Degeneration (SUSHI)

This is an open label, non-controlled, dose-escalating study assessing the safety, tolerability, and bioactivity of a single intravitreal (i.vt.) injection of RBM-007 in approximately nine subjects with exudative age-related macular degeneration.

Study Overview

• Status: Completed
• Conditions: Age-related Macular Degeneration
• Intervention / Treatment: Drug: RBM-007 Injectable Solution

Detailed Description

Nine subjects in three dose cohorts (3 subjects each cohort) will receive a single i.vt. injection of RBM-007 in the study eye. Subjects will be followed through Day 56.

• Study Type: Interventional
• Enrollment (Actual): 9
• Phase: Phase 2; Phase 1

Contacts and Locations

Study Locations

• United States
  • California
    • Sacramento, California, United States, 95841
      • Retinal Consultants Medical Group
    • Sacramento, California, United States, 95819
      • Retinal Consultants Medical Group
    • Stanford, California, United States, 94303
      • Stanford University
    • Walnut Creek, California, United States, 94704
      • Bay Area Retina Associates

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 53 years to 97 years (Adult, Older Adult)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

Description

Inclusion Criteria:

1. Male or female 55 years of age or older on the date of signing the informed consent form and able and willing to comply with all treatment and follow-up study procedures.
2. At Screening Visit, subjects must meet all the following inclusion criteria:
3. Must have had prior treatment in the study eye with any intravitreal vasoactive endothelial growth factor (VEGF) medication (at least 3 anti-VEGF) treatments within the prior 2-6 months), throughout which clinical examination and SD-OCT imaging has shown recurrent or persistent exudative activity, as shown by the presence of intraretinal or subretinal fluid, and/or subretinal exudation or hemorrhage.
4. Best corrected visual acuity of 65 to 20 Early Treatment of Diabetic Retinopathy Study (ETDRS) letters (20/50 to 20/400) in the study eye.
5. Presence of significant subretinal fluid and/or cystoid macular edema secondary to exudative age-related macular degeneration as assessed by optical coherence tomography in the study eye, with a minimum of 300 µm within the central subfield.
6. Total lesion size of ≤9 disc areas, lesion containing ≤50% hemorrhage and ≤50% subretinal fibrosis and ≤50% retinal pigment epithelial atrophy in the study eye.

7. Reasonably clear media and reasonable fixation ability in the study eye to allow for good quality tomography and fundus photography.

   At Baseline Visit (Day 0), subjects must meet all the following inclusion criteria:

8. Best Corrected Visual Acuity (BCVA) of 65 to 20 ETDRS letters (20/50 to 20/400) in the study eye.
9. Presence of significant subretinal and/or intraretinal fluid secondary to exudative age-related macular degeneration as assessed by SD-OCT in the study eye, with a minimum of 300 µm within the central subfield.
10. Total lesion size of ≤9 disc areas, containing ≤ 50% hemorrhage and ≤ 50% fibrosis and ≤ 50% retinal pigment epithelial atrophy in the study eye.

Exclusion Criteria:

Ocular exclusion criteria:

1. BCVA better than 65 ETDRS letters (20/50) in the study eye.
2. BCVA worse than 20 ETDRS letters (20/400) in study eye.

3. Fellow eye BCVA worse than 35 ETDRS letters (20/200).

   Use of any of the following treatments to the study eye:

4. Intravitreal anti-VEGF injection (ranibizumab, aflibercept or bevacizumab) in the study eye within the past 4 weeks or less prior to Baseline Visit and RBM-007 injection.
5. Intravitreal or periocular corticosteroid, within 3 months prior to Baseline Visit (Day 0) and throughout the study;
6. Fluocinolone acetonide intravitreal implant, within 12 months prior to Baseline Visit (Day 0) and throughout the study;
7. Visudyne® (verteporfin) photodynamic therapy, within 3 months prior to Baseline Visit (Day 0) and throughout the study.
8. Uncontrolled or advanced glaucoma, defined by an intraocular pressure (IOP) of >21 mmHg or cup/disc ratio > 0.8 while on medical therapy, or chronic ocular hypotony (<6 mmHg) in the study eye.
9. Evidence of ocular disease other than exudative AMD in the study eye that may confound the outcome of the study (e.g., active diabetic retinopathy, posterior uveitis, adult vitelliform dystrophy, moderate/severe myopic degeneration).
10. History of vitrectomy surgery in the study eye.
11. Anticipated need for any ocular surgery involving the study eye during the course of the study.
12. Nd:YAG laser capsulotomy within 28 days prior to Baseline Visit (Day 0) in the study eye.
13. Intraocular surgery, including lens removal or ophthalmologic laser procedure, within 90 days prior to Baseline Visit (Day 0) in the study eye.
14. Ocular or periocular infection in either eye.
15. Pupillary dilation inadequate for good quality fundus photography in the study eye.
16. Media opacity that would limit clinical visualization, fundus photography, fluorescein angiography, or SD-OCT evaluation in the study eye.
17. History of herpetic ophthalmic infection in the study eye or adnexa.
18. Presence of known toxoplasmosis or toxoplasmosis scar in either eye.
19. Presence or history of any form of ocular malignancy including choroidal melanoma in the study eye.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Non-Randomized
• Interventional Model: Single Group Assignment
• Masking: None (Open Label)

Number of Arms

3

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: RBM-007 Injectable Solution - 0.2 mg; No additional information.	Drug: RBM-007 Injectable Solution; (No additional description)
Experimental: RBM-007 Injectable Solution - 1.0 mg; No additional information.	Drug: RBM-007 Injectable Solution; (No additional description)
Experimental: RBM-007 Injectable Solution - 2.0 mg; No additional information.	Drug: RBM-007 Injectable Solution; (No additional description)

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Ocular Safety as Assessed Using Biomicroscopy to Investigate Ocular Tolerability	Biomicroscopy is used by an ophthalmologist to assess the health of the front of the eye. The measure is the number of subjects with abnormal findings that were not present at screening.	Day 56
Ocular Safety as Assessed Using Ophthalmoscopy to Investigate Ocular Tolerability	Ophthalmoscopy is used by an ophthalmologist to assess the health of the back of the eye. The measure is the number of subjects with abnormal findings that were not present at screening.	Day 56

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Ocular Tolerability as Assessed by Number and Nature of Adverse Events	Adverse events (ocular or non-ocular)	Day 56

Collaborators and Investigators

• Sponsor: Ribomic USA Inc
• Investigators: Study Director: Yusuf Ali, Ph.D., Ribomic USA Inc

Study record dates

Study Major Dates

• Study Start (Actual): August 29, 2018
• Primary Completion (Actual): June 26, 2019
• Study Completion (Actual): June 26, 2019

Study Registration Dates

• First Submitted: July 18, 2018
• First Submitted That Met QC Criteria: August 13, 2018
• First Posted (Actual): August 16, 2018

Study Record Updates

• Last Update Posted (Actual): January 5, 2021
• Last Update Submitted That Met QC Criteria: December 31, 2020
• Last Verified: December 1, 2020

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Eye Diseases; Retinal Degeneration; Retinal Diseases; Macular Degeneration
• Other Study ID Numbers: RBM-007-001

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: Undecided

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: Yes
• Studies a U.S. FDA-regulated device product: No